Exagen Inc. (NASDAQ: XGN)

March is Autoimmune Awareness Month, and a reminder that symptoms are often easy to miss. There are 100+ autoimmune conditions—from rheumatoid arthritis and lupus to multiple sclerosis and type 1 diabetes. Many overlap in symptoms, and getting to a clear diagnosis can take years. ~50 million Americans are estimated to be living with an autoimmune condition. Awareness supports earlier recognition, more research, and better tools for patients and clinicians. This month, we’ll share weekly posts on the realities of complex autoimmune presentations, and how AVISE® CTD can help physicians move from early symptoms to more confident diagnostic decisions. #AutoimmuneAwarenessMonth #ChronicIllness #AutoimmuneDisease #EarlyDiagnosis #Diagnostics

Exagen reports strong Q3 2025 results! investors.exagen.com/news-releases/…

We look forward to hearing Andrea Fava, MD, present his groundbreaking research, "Urinary Tenascin C Predicts Kidney Function Loss in Lupus Nephritis" at ACR Convergence 2025. This 15-minute Plenary Talk will highlight novel biomarkers with the potential to enhance early detection and improve management of lupus nephritis. 📍Session Details: • Location: McCormick Place, Lower Level, Exhibit Hall F2 • Date & Time: October 27th, 2025, 6:30-6:45 AM 🎤 Presentation Title: • Urinary Tenascin C Predicts Kidney Function Loss in Lupus Nephritis #ACRConvergence2025 #LupusNephritis #AutoimmuneDiagnostics #Rheumatology #Exagen #LupusResearch #AviseLupus

We're honored to host an Innovation Theater Presentation at ACR Convergence 2025. Join us as we explore the science shaping the future of autoimmune diagnostics. 📍 Event Details • Location: McCormick Place Convention Center | Chicago, IL • Date & Time: Monday, October 27 | 2:30-3:15 PM CDT • Theater: Innovation Theater A 🎤 Presentation Title: AVISE® CTD: A Decade of Validation Driving Lupus Diagnostic Accuracy, Seronegative RA Biomarker Innovation, and Novel T Cell Biomarkers for Lupus. 🗣️ Featured Speakers: • Alvin Wells, MD, PhD, FACP, FACR • Vasileios Kyttaris, MD, PhD, FACR We look forward to sharing new insights that continue to advance lupus and rheumatoid arthritis diagnosis and patient care. #ACRConvergence2025 #Rheumatology #Innovation #AutoimmuneDiagnostics #AVISECTD #Exagen

Exagen is proud to announce that we will be attending and presenting at ACR Convergence 2025 inChicago from October 24-29. 📍 Stop by booth #1228 to learn how we're leading the science of autoimmune disease diagnostics. At Exagen, our mission is simple: to improve the lives of patients suffering from autoimmune diseases by delivering innovative, trusted diagnostic solutions that empower physicians with clarity and confidence. We look forward to connecting with the rheumatology community, sharing our latest advancements, and discussing how together we can help drive earlier, more accurate diagnoses and better patient outcomes. #ACR25 #Exagen #Avise #Autoimmune #Diagnostics #Rheumatology #Lupus #RA

Peptidylarginine deiminases (PADs) play a crucial role in the production of citrullinated proteins, the hallmark autoantigens of Rheumatoid Arthritis (RA). Anti-PAD4 autoantibodies target a key enzyme involved in the citrullination process. Unlike traditional biomarkers, anti-PAD4 can be present in patients who are seronegative for RF and anti-CCP, helping clinicians identify RA earlier in the disease course. By providing additional diagnostic and prognostic insight, anti-PAD4 supports earlier intervention and greater confidence when differentiating RA from other inflammatory arthritides, especially in clinically ambiguous cases. Learn more about Exagen’s newest biomarkers: avisetest.com/provider/avise… #RA #autoimmunedisease #AVISE #rheumatoidarthritis #SeronegativeRA

Peptidylarginine deiminases (PADs) play a crucial role in the production of citrullinated proteins, the hallmark autoantigens of Rheumatoid Arthritis (RA). Anti-PAD4 autoantibodies target a key enzyme involved in the citrullination process. We're excited to announce the addition of two new innovative seronegative rheumatoid arthritis (RA) biomarkers, anti-PAD4 IgG and IgA, now included with every AVISE® CTD test. With up to 30% of RA patients testing negative for conventional biomarkers anti-CCP and rheumatoid factor, anti-PAD4 biomarkers provide greater diagnostic sensitivity. This allows clinicians to identify seronegative RA earlier, enhance diagnostic clarity, and gain valuable prognostic insights to help guide clinical decision-making. Available starting today. Learn more: avisetest.com/provider/avise… #RheumatoidArthritis #RA #AutoimmuneDisease #AVISE #PAD4 #SeronegativeRA

Don’t forget to register for our upcoming webinar on innovative and comprehensive serological testing in autoimmune disease diagnostics. Learn how AVISE® CTD is helping improve diagnostic accuracy and patient outcomes—secure your spot today. #AviseCTD #autoimmunetesting #rheumatology #precisiondiagnostics #lupus #ra xtalks.com/webinars/beyon…

Join our webinar to learn how innovative serological testing is transforming diagnostic accuracy for #lupus, #RA, and other connective tissue diseases. Gain practical insights through real-world case studies, and learn how enhanced diagnostics via AVISE® CTD are improving patient outcomes and streamlining clinical practice —register now! #autoimmunedisease #rheumatology #rheumeducation #precisiondiagnostics #lupus #rheumatoidarthritis xtalks.com/webinars/beyon…

Exagen reports strong Q2 2025 results! investors.exagen.com/press-releases…

We are pleased to announce that our latest research collaboration with @DukeUniversity was published in Lupus Science & Medicine. Read the full article here: lupus.bmj.com/content/lupuss… #Lupus #SLE #AutoimmuneDisease #HCQ #PrecisionMedicine #LupusResearch #LupusScience #AVISE

Exagen's Brittany Partain was recently featured in @CLPMag where she discussed the promising new research on TC4d, a novel biomarker that can identify lupus cases missed by traditional SLE lab tests. Read the article: clpmag.com/disease-states… #Lupus #Diagnostics #Biomarkers

Please join us in welcoming Michael Mahler, PhD to the team! We’re excited for what’s ahead. #PrecisionMedicine #Innovation #AVISE #rheumatology

A huge thank you to everyone who participated in our "Give for Lupus" blood drive with the American @RedCross and helped spread awareness all month long. Let’s keep the momentum going - supporting those impacted by lupus is a year-round commitment. #LupusAwarenessMonth

T Cell biomarkers are emerging as powerful tools in the early detection of #lupus. Learn more: ow.ly/wVr650VS0bA #rheumatology #LupusAwarenessMonth

Our webinar is TOMORROW! Don’t miss your chance to join us for an insightful session on the effectiveness of RA33 autoantibodies in clinical practice. #RheumatoidArthritis #Rheumatology #MedicalResearch ow.ly/RuUa50VQnxB

Exagen put on purple for #WorldLupusDay to shine a light on this invisible illness through science, awareness, and support. #LupusAwarenessMonth

Explore what's new in #rheumatoidarthritis diagnostics with Dr. Alvin Wells and Tyler O'Malley in this expert-led educational session. Don't miss out - Register today! ow.ly/Z1kv50VO7Qg #PrecisionMedicine #Rheumatology

Read more: ow.ly/PfxH50VN5AM

May is Lupus Awareness Month. Join us in raising awareness for the millions affected by this complex #autoimmunedisease. Ongoing research and development leads to earlier diagnosis and better care. avisetest.com #WorldLupusDay #LupusAwareness #ShinePurple